Breast cancer patients covered by insurance: 83 million won → 4.17 million won = South Korea

ENHERTU, a new injectable breast cancer drug, will be covered by health insurance in South Korea starting next month, and patients will have to pay 4.17 million won (approx.
It is expected to decrease to 460,000 yen). On the 28th, the Ministry of Health and Welfare announced that after deliberation by the Health Insurance Policy Deliberation Committee, Korea Daiichi Sankyo's Enhertz 100mg (ingredients: trastuzumab, deruxteca)
The company announced that it has decided to register for health insurance benefits that cover some breast cancer and stomach cancer. Enhertz was confirmed to be effective in increasing progression-free survival (PFS) when administered to breast cancer patients.
. PFS refers to the length of time a patient survives without disease progression compared to existing drugs. Breast cancer is the number one cause of death for women in their 40s and 50s in South Korea. With this benefit registration, breast cancer foundation
The annual cost of administering Enhertz for one quasi-patient will be significantly reduced from 83 million won to 4.17 million won. The scope of benefits for infertility treatment drugs will also be expanded. Progesterone, a progestin used for infertility treatment,
Insurance coverage for Gobelis and Ruberis has expanded, allowing more patients to benefit from insurance. Along with this, the Ministry of Welfare has announced a huge number of organ and hematopoietic stem cell transplant patients.
It has also been decided that insurance will be extended to cover drugs for the treatment of cell virus infections and drugs for the treatment of severe smallpox.